Claris Lifesciences has received approval from the US health regulator for Metoprolol Tartrate injection used for treating angina and hypertension.
The company has received abbreviated new drug application (ANDA) approval from the United States Food and Drug Administration (UDFSA) for Metoprolol Tartrate injection in the strength of 1mg/ml in 5 mg glass vials, Claris Lifesciences today said in a filing to the BSE.
The product is used for treating cardiac conditions such as angina and hypertension. It is also used for treating, or preventing, heart attack.
The company currently has a total 32 ANDA filings with 10 ANDA approvals, Claris Lifesciences said.
Claris Lifesciences is a leading sterile injectables pharmaceutical company having presence in 98 countries.
Shares of Claris Lifesciences were trading at Rs 180.25 apiece on the BSE in the afternoon trade, up 0.81 per cent from their previous close.